Healthtech Investors

What are Healthtech investors, and what do they look for?

The first question a healthtech investor asks is who pays, and the answer determines everything that follows. A product sold to a hospital, to an insurer, to an employer or directly to a patient is four different companies with four different sales cycles, and investors specialise accordingly. Founders who describe their market as healthcare rather than naming the budget holder tend to lose the room early. Regulatory classification is the next filter. Whether your product is a medical device, clinical decision support, or a wellness tool making no clinical claim changes your cost and timeline to market by years. Investors want to see that you have taken a considered position on this, with proper advice behind it, rather than hoping to stay below a threshold you have not tested. Evidence is the third pillar and the most underestimated. Healthcare buyers do not purchase on a demo. They purchase on outcomes data, preferably published, preferably not generated by you alone. Expect questions about what evidence you hold, what evidence the buyer requires, and how long the gap between the two takes to close. Integration reality closes the list. Clinical software lives or dies on whether it connects to the systems already installed, and the incumbents controlling those systems have limited enthusiasm for making that easy. A credible plan here, whether through standards, partnership, or a deliberate decision to sit outside the patient record entirely, separates companies that scale from companies that pilot indefinitely.

Why Healthtech is attracting investor interest

Demographics do most of the argument here. European populations are ageing, chronic disease prevalence is climbing, and the clinical workforce is shrinking relative to demand. Health systems cannot hire their way out of that gap, which leaves technology as one of the few available levers. Investors find this persuasive precisely because it does not depend on a trend continuing. It depends on arithmetic that is already fixed. The pandemic accelerated something more specific. Reimbursement pathways for remote consultation and monitoring appeared in several European systems considerably faster than anyone expected, and institutional resistance to digital delivery weakened in a way that has not reversed. Once a payment pathway exists, a market exists, and categories that had been stuck for a decade became fundable within about two years. Sustained budget pressure has done the rest. Public health systems across Europe are financially strained, which makes them unusually receptive to anything demonstrably cheaper and unusually slow to actually buy it. Investors have learned to underwrite that contradiction rather than be surprised by it, and the good ones will ask how you plan to survive the gap between enthusiasm and procurement. There is a data argument too. European health systems hold longitudinal population data of a depth that is rare globally, and the frameworks governing access, while restrictive, are becoming clearer. Companies that can operate inside those constraints hold a research asset that competitors elsewhere cannot easily replicate.

Which funding stages Healthtech investors are active at

Stage behaviour in healthtech is dictated by regulatory and evidence milestones rather than by revenue, which makes it look unusual against software norms. Pre-seed and seed rounds fund a team, a clinical hypothesis and usually a first study or a regulatory strategy. Investors at this stage are underwriting the founding team's clinical credibility as much as anything else, and a practising clinician or a serious academic on the founding team materially changes how a round is received. Series A typically requires evidence rather than scale: a completed study, a regulatory clearance, or a paying institutional customer that survived procurement. This is where a large share of healthtech companies stall, because the evidence generation takes longer than the runway raised at seed. Planning the seed round against the evidence milestone rather than against a revenue target is the single most useful adjustment founders can make. Series B and beyond turn on repeatability of the sales motion into institutional buyers, which in European healthcare means surviving tender processes and reference-selling between systems. Investors want proof that the second and third customer took less time than the first. Growth-stage capital in European healthtech is thinner than in software, and later rounds frequently involve strategic investors, health system venture arms and specialist funds from the US. Reimbursement-backed models attract a distinct set of growth investors who underwrite payer relationships rather than user growth.

Typical check and round sizes in Healthtech

Numbers here are less transferable than in most sectors, because a company pursuing a medical device classification and one selling an unregulated workplace wellbeing product have almost nothing in common financially, despite sharing the healthtech label. The dominant variable is the regulatory and evidence path. A clinical study costs real money and takes real time, and it is a fixed obligation rather than something that flexes with growth. Rounds in regulated healthtech are therefore sized against a specific milestone: completing a trial, achieving a clearance, or reaching a reimbursement decision. Founders should present the raise in exactly those terms, since investors are underwriting the milestone rather than the runway. The second variable is the length of the sales cycle. Selling into public health systems in Europe involves procurement processes that run considerably longer than commercial software cycles, and the capital required is largely a function of how many of those cycles you must survive before revenue arrives. Underestimating this is the most common cause of a bridge round. Unregulated or lightly regulated products, including workplace health, wellbeing and administrative tooling, raise on conventional software patterns and should be benchmarked against software rather than against healthcare. Where you need real comparables, look at recent European rounds in your specific regulatory class and payer model. Aggregate healthtech figures blend device companies, care delivery businesses and software into an average that describes none of them.

Types of investors active in Healthtech

What Healthtech investors look for in diligence

Healthtech diligence is longer than software diligence and draws on outside expertise, so expect clinical and regulatory advisers to read your material rather than only the investment team. Evidence quality comes first and gets examined critically. Study design, sample size, whether the comparison arm was meaningful, who conducted the analysis, and whether results have been peer reviewed. Investors distinguish sharply between a pilot that produced encouraging numbers and a study that would persuade a sceptical clinician, and they will ask which one you have. Regulatory position is assessed independently of your own view. Expect questions on classification under the medical device framework, your conformity assessment route, notified body engagement and timelines. Companies that have taken an aggressive classification position without documented advice find this stage uncomfortable. Reimbursement analysis follows: which codes apply, in which countries, whether the decision is national or regional, and what precedent exists for products like yours. A vague reimbursement story is one of the most common reasons a promising healthtech deal stalls. Data protection receives heavier scrutiny than in other sectors because health data is a special category under GDPR. Legal basis, consent mechanics, data residency, processor agreements and what happens to data used for model training are all standard questions now. Clinical safety governance and post-market surveillance obligations get checked as operating functions rather than documents. Finally, procurement evidence. Investors want to see that a real institution completed a full purchasing process, not that a department ran a pilot on discretionary budget.

How to build a fundraising strategy as a Healthtech startup

Plan the raise around an evidence milestone and say so explicitly. Healthtech investors are underwriting your ability to reach a regulatory clearance, a study result or a reimbursement decision, and a round framed in those terms is far easier to evaluate than one framed around months of runway. Separate your funding sources by what they are good at. Grants and public innovation funding are well suited to evidence generation, which equity investors are reluctant to fund and which dilutes badly. Across most of Europe there is substantial non-dilutive money available for exactly this purpose, and companies that combine the two arrive at Series A having spent less equity to reach the same point. Build the clinical and regulatory bench before you need it. A named clinical adviser, a regulatory consultant with relevant approvals behind them, and an advisory board with genuine standing all reduce perceived risk more cheaply than any other action available to you. Be specific about the payer from your first slide. Naming the budget, the decision-maker and the procurement route immediately signals that you understand the market, and it filters out investors who cover a different part of the sector before either side wastes time. Sequence markets deliberately. European health systems differ enough that success in one is weak evidence for the next, and investors know it. A plan that treats Europe as a single market reads as inexperience. A plan that names two systems, explains why those two, and shows what transfers between them reads as competence. Finally, budget honestly for procurement time. The most common failure is a company with a good product, real evidence and no runway left, because the purchase took eleven months longer than the plan assumed.

Common mistakes founders make raising Healthtech capital

Calling something a wellness product to avoid regulation, while making claims that clearly imply clinical benefit, is the error investors punish most severely. It suggests either that you have not taken advice or that you have taken it and ignored it, and both are disqualifying for a serious investor. Presenting pilots as commercial traction is the next most common. Health systems run pilots constantly, often on innovation budgets that have no relationship to purchasing. A pilot that ended without a procurement process is evidence of interest, not of a market, and experienced investors will draw that distinction for you if you do not. Underestimating the sales cycle is close behind. Founders routinely model six-month enterprise cycles for buyers whose procurement rules make that impossible, then run out of money in month fourteen with the deal still progressing. Building for the clinician while selling to the administrator, or the reverse, is a subtler failure. The person who loves your product and the person who signs the contract are frequently different people with opposed incentives, and a go-to-market plan that has not addressed the tension is not a plan. Treating data protection as a later problem creates the worst kind of rework, since health data obligations shape architecture rather than sitting on top of it. Finally, entering multiple European countries at once. Each system has its own regulator, procurement culture, reimbursement logic and language. Companies that spread themselves across three and establish themselves in none are a well-known pattern, and one investors ask about directly.

How Healthtech investment differs across Europe

The UK combines a single large public system with a comparatively centralised route to adoption, which makes it attractive in theory and slow in practice. Evaluation frameworks and national procurement can take a long time, but a product adopted at national level scales in a way that is difficult to replicate in more fragmented markets. London also holds the deepest concentration of healthtech investors in Europe. Germany stands out for having created an explicit reimbursement pathway for digital health applications, which gave founders something rare: a defined process with a defined outcome. The requirements are demanding and the evidence bar is real, but the existence of a codified route has drawn considerable investor attention to German digital health. France pairs a large public system with strong state backing for health innovation and an active domestic investor base. Adoption tends to move through hospital networks and regional bodies rather than nationally, so early commercial planning has to be geographically specific. The Nordics are the easiest place in Europe to run a clinical study and to integrate with existing records, thanks to mature digital infrastructure and population registries. Markets are small, so companies there internationalise early, and investors expect a plan that reflects it. The Netherlands and Belgium offer well-organised systems and high digital maturity, and are often used as a first market precisely because processes are predictable. Southern and Central Europe generally have longer procurement cycles and tighter budgets, with growing engineering strength. Companies frequently build there and sell north, which works commercially but means local investors at Series A are scarce and later rounds usually come from elsewhere.